Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%

Directive transparence : information réglementée

22/02/2021 19:00